Severity Of Sexual Dysfunction Research Articles

(113) Investigating the Prevalence of Erectile Dysfunction in Patients with Non-Alcoholic Fatty Liver and Its Relationship with the Severity of Fatty Liver

Abstract Introduction Today, the relationship between erectile dysfunction in men and the pathogenesis process in the field of metabolic syndrome is of interest. Non-alcoholic fatty liver disease is one of the diseases related to metabolic syndrome, which has a high prevalence. This study was conducted with the aim of evaluating the prevalence of erectile dysfunction in men with non-alcoholic fatty liver disease and investigating the relationship between its severity and the grading of liver complications. Objective In this research, the frequency of erectile dysfunction and decreased libido and sexual satisfaction in patients with non-alcoholic fatty liver disease have been investigated and compared with the control group. Also, the relationship between the severity of sexual dysfunction and fatty liver grading has been investigated. Methods In this study, 1200 patients with non-alcoholic fatty liver disease were randomly selected and participated in this study between 2019 and 2022. In order to investigate sexual disorders, the standard male sexual performance questionnaire was used along with the demographic questionnaire. Results The results of this study showed that the indicators of male sexual dysfunction in patients with non-alcoholic fatty liver have a high prevalence (44.5%). Also, the severity of erectile dysfunction has a significant relationship with the severity of non-alcoholic fatty liver disease (pv=0.002). Conclusions A holistic view of the health category requires that in the treatment of medical disorders, the effective factors and consequences of the disorder should be considered. Paying attention to the diagnosis and treatment of sexual disorders in the treatment process will be one of the most important aspects of the patient's health; Because erectile dysfunction in men, apart from the effect on sexual relations, will have destructive consequences on their psychological indicators and quality of life. On the other hand, it is possible to improve the quality of patients' health by modifying the lifestyle and interdisciplinary cooperation. Disclosure No.

Sexual Dysfunction in Depressed Patients Presenting to Psychiatry Ward/Opd

Background: Depression is a pervasive mental health issue that significantly affects individuals' quality of life, often accompanied by sexual dysfunction. Previous research has highlighted the complex relationship between depression and sexual dysfunction, but there remains a need for further investigation into their co-occurrence and the impact of treatment modalities on these conditions. Objective: This study aims to explore the prevalence and severity of sexual dysfunction among depressed patients, examine the correlation between the severity of depression and sexual dysfunction, and assess the effects of different medication regimens on sexual health. Methods: A descriptive study design was employed, examining 250 depressed patients seeking treatment at the Psychiatry Ward and Outpatient Department of Khyber Teaching Hospital, Peshawar, from September 2022 to August 2023. Participants were selected through purposive sampling, with inclusion criteria being individuals aged 18 years and above, diagnosed with depression according to DSM-5 criteria. The Arizona Sexual Experiences Scale (ASEX) and the Patient Health Questionnaire-9 (PHQ-9) were administered to evaluate sexual dysfunction and depression severity, respectively. Data analysis was conducted using SPSS version 25, employing descriptive statistics and Pearson correlation coefficients to analyze the data. Results: The study found that 48% of participants experienced significant sexual dysfunction in the domain of desire, with 68% of participants having moderate to severe depression. A strong correlation was observed between the severity of depression and sexual dysfunction, with Pearson correlation coefficients of 0.65 for desire, 0.72 for arousal, and 0.68 for satisfaction (p<0.001 for all). Medication analysis revealed that 45% of patients on antidepressants, 60% on antipsychotics, and 50% on combination therapy reported sexual dysfunction. Conclusion: The findings confirm the high prevalence of sexual dysfunction among depressed individuals and its strong association with the severity of depression. The study underscores the necessity of adopting an integrated treatment approach that addresses both depression and sexual dysfunction, highlighting the importance of considering the side effects of psychiatric medications on sexual health.

The comparison of sexual function in types I and II of female genital mutilation

BackgroundFemale genital mutilation has many sexual, physical, and psychological consequences. The present study aimed to examine the relationship between Female Genital Mutilation/Cutting (FGM/C), and Sexual Function among circumcised women in Sardasht City, Iran.”MethodsIn this present cross-sectional study, 197 women who were mutilated entered the study by simple random sampling from two healthcare centers in Sardasht, Iran. A gynecologist first performed a genital examination to identify the type of female genital mutilation of participants. Subsequently, Socio-demographic and FGM/C-related characteristics checklist and the female sexual function index questionnaire were completed by interview method. Data were analyzed using SPSS 23 software.ResultsType I and II of female genital mutilation were performed in 73.1 and 26.9% of the participants, respectively. The age range of performing female genital mutilation in type I and II of female genital mutilation was 4–10 years old in 67.4% and 71.1% respectively. Traditional practitioners/local women carried out the circumcision in all of the participants, and Sunnah/tradition was reported as the most common reason for doing this procedure. The average total score of FSFI index in type I and II of female genital mutilation was 23.5 ± 2.0 and 17.4 ± 2.39, respectively. In all domains of FSFI, women with type II of female genital mutilation obtained lower scores than women with type I.ConclusionCircumcised women have reduced scores in all domains of FSFI, and the severity of sexual dysfunction is related to the type of FGM/C. Considering the prevalence of female genital mutilation and its adverse effects, it is imperative to initiate cultural improvements through education and awareness. By educating and raising awareness among individuals about this issue, we can foster positive changes and address the problem effectively.

A Study of Sexual Dysfunction and Quality of Life in Female Patients on Selective Serotonin Reuptake Inhibitor (SSRI)

Context: Sexual dysfunction is one of the most common and disconcerting side effect during treatment with Selective serotonin reuptake inhibitors (SSRIs). Sexual side effects from these medications have significant impact on self esteem, quality of life and can lead to non compliance and relapse in long term treatment. Aims: To study prevalence, severity of sexual dysfunction and its possible association with quality of life in female patients on treatment with SSRI for depression and anxiety. Materials and Methods: This was an observational, cross sectional, single-centre study. Hundred consecutive female patients who were sexually active, on SSRIs for six weeks or more were recruited. Diagnosis of Major depressive disorder (MDD), Anxiety disorders and female sexual dysfunction was done by clinician administered interview as per Diagnostic and Statistical Manual of mental disorders (DSM 5). The patients were further assessed for demographic details, CSFQ-F-C, HAM-D, HAM-A and WHOQOL-BREF scales for sexual dysfunction, depression, anxiety and quality of life respectively. p value of <0.05 was considered to be statistically significant. Results: Prevalence of sexual dysfunction was 84%. Patients with sexual dysfunction scored significantly lower value in social relationships (p= 0.0002) and environment (p= 0.033) domains of quality of life. Frequency of sexual dysfunction among patients on fluoxetine was 86.20%, on escitalopram was 86.76% and on sertraline was 66.6%. Frequency of sexual dysfunction was more with higher dose of SSRIs. Conclusions: Patients on various SSRIs experienced sexual dysfunction and had poor quality of life. Frequency of sexual dysfunction was more with higher doses of SSRIs. Keywords: Sexual dysfunction, Selective serotonin reuptake inhibitors, Depression, Anxiety, quality of life.

P137 The prevalence and severity of sexual dysfunction in male IBD patients: an observational single-center study

Abstract Background Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are lifelong disabling disorders with a significant impact on the quality of life. Previous studies reported sexual dysfunction (SD) could have a remarkable prevalence of about 25-45% in male IBD population, compared to 10-20% in the general population of the same age. However, this topic has not attracted widespread attention, and thus research studies are scarce. The aim of the study was to determine the rate and the severity of SD in a cohort of male IBD patients and to identify the associated risk factors. Methods This is an observational single-center study. From July 2021 to June 2022, IBD patients, who were attending scheduled visits, were invited to fill the International Index of Erectile Function (IIEF) questionnaire. Clinical data, including disease behaviour, treatment history and previous surgery, were collected. Both descriptive and inferential statistical analyses were carried out. Results A total of 61 male IBD patients, encompassing 33 with CD and 28 UC, were enrolled. Overall, the median age was 33.8 years (range, 19.7 – 63.7); the median body mass index (BMI) was 26.5 kg/m2 (range, 17.6 – 31.9). Almost half of the subjects were active or former smokers (49.1%). The great majority (81.9%) were receiving biological therapies, less than half had an history of IBD-related surgery (42.6%). The median total IIEF score was 64 (range, 18-75). Totally, 25.4% of the included patients reported having erectile dysfunction (ED), according to erectile function subscore. Univariate analysis showed age (p = 0.001), calprotectin levels (p<0.05) and biological therapy duration (p<0.05) as variables significantly associated with total IIEF score; age (p = 0.003) and calprotectin levels (p<0.05) were also significantly correlated with erectile function subscore. At multivariate level, age and calprotectin levels were confirmed to significantly influence both total IIEF score (p = 0.003 and p = 0.002, respectively) and erectile function subscore (p = 0.001 and p = 0.01, respectively). Conclusion Nearly a quarter of included IBD patients were found having ED, while rates of 5-15% in healthy subjects of the same age has been previously reported in literature. Based on our results, gastroenterologists should assess the sexual function of IBD patients and, when indicated, prompt referral for andrological investigation should be considered to improve their quality of life.

Assessment of Quality of Sexual Life in Male Patients with Psoriasis

Introduction: Psoriasis is a global burden of disease characterized by the presence of well circumscribed erythematous papule & plaque of various size & shape, covered by silvery scales. It not only hampers the quality of life but also hampers the sexual function. Men who have psoriasis may be more likely to have sexual problems, such as sexual apathy, orgasmic dysfunction, erectile dysfunction (ED), etc. Stress tends to be a triggering or aggravating factor in psoriasis. In addition, the disease itself can generate emotional stress because of its lesions. It is thought that chronic inflammation. Results in metabolic diseases and proinflammatory cytokines give rise to the development of atherogenesis. Pelvic arterial atherosclerosis is another cause of sexual dysfunction. This study was designed to determine the impact of moderate to severe psoriasis on quality of life and sexual dysfunction in male patients. Methods: This case control study was conducted in Department of Dermatology and Venereology, Dhaka Medical College Hospital, among the 100 patients. Group- A was cases (male married patients age between 24 years and 60 years with history of moderate to severe psoriasis) and group-B were control (male married patients age between 24 years and 60 years without psoriasis). Then variables were analyzed and compared. Data was processed and analyzed with the help of computer program SPSS and Microsoft excel. Quantitative data expressed as mean and standard deviation and qualitative data as frequency and percentage. Comparison was done by tabulation and graphical presentation in the form of tables, pie chart, graphs, bar diagrams, histogram & charts etc. Results: It was found that majority of the patients i.e. 46% were between 34-43 years, mean age was found to 41.7±11.3 years. No significant difference in age and other demographic profile was observed between groups. Prevalence of IHD (8.0%), stroke (14.0%), dyslipidaemia (54.0%), neuropathy (26.0%) and PVD (8.0%) were higher in case or psoriatic patients. On evaluation of Dermatology Life Quality Index (DLQI), majority of patients (54%) score was 6-10, followed by 24.0% had score 2-5 and 22.0% of patients had score 11-20 or very large effect on patient’s life. Prevalence of erectile dysfunction was 36.0%, prevalence of orgasmic dysfunction was 24.0%. On multivariate analysis which was done by ordinal logistic regression procedure. The attributes found to be positively associated with sexual dysfunction severity in the multivariate model were patient’s age, disable status, sedentary work, duration of illness, etc. Conclusion: Erectile dysfunction and orgasmic dysfunction are common in psoriatic male patients. There is association with other comorbidities. J Bangladesh Coll Phys Surg 2022; 40: 233-228

Prevalence and severity of sexual dysfunction in women experiencing urinary incontinence with and without breast cancer: A matched control study

Symptoms of either female sexual dysfunction (FSD) or urinary incontinence (UI) after breast cancer treatment are reported to be common. Despite this, the prevalence and severity of FSD in women who experience UI after breast cancer treatment has not been investigated. The aim of this study was to compare the prevalence and severity of FSD in women with and without breast cancer who experience UI. A secondary analysis of data from a larger cross-sectional study was undertaken. 21 pairs of sexually active women with and without breast cancer who experienced UI were matched according to age, body-mass index and parity. The severity of FSD was assessed using the Female Sexual Function Index (FSFI). Participant demographics, prevalence of FSD, and FSFI scores were reported descriptively. Differences in prevalence rate of FSD and FSFI scores between women with and without breast cancer and UI were analysed using Wilcoxon signed-rank or McNemar’s tests. Participants with breast cancer who experienced UI reported significantly higher rates of FSD ( n = 19/21, 90%) compared to participants without breast cancer with UI ( n = 10/21, 48% p = 0.0028). Participants with breast cancer and UI had a significantly lower overall FSFI score (median = 18.8, IQR = 12.5) compared to those without breast cancer with UI (median = 25.9, IQR = 10, p = 0.0096). They also reported lower arousal, less lubrication, lower satisfaction and more pain during sexual activity compared to participants without breast cancer who experienced UI. Participants with breast cancer who experienced UI had a higher prevalence and severity of FSD than participants without breast cancer with UI. They reported having lower arousal, lubrication, satisfaction and more pain during sexual activity. These preliminary results suggest larger studies to investigate sexual function in women with breast cancer and UI are warranted.

Sexual Functioning Among Adults with Chronic Pain: Prevalence and Association with Pain-Related Outcomes.

Prior research indicates that sexual functioning and chronic pain commonly coexist and impact each other; however, there are limitations in current research as to the prevalence and severity of sexual dysfunction in patients with chronic pain. This study used detailed measures across multiple domains of sexual functioning to describe the prevalence and correlates of self-reported sexual functioning among individuals with chronic pain presenting for treatment at a multidisciplinary pain management center (N = 247). Domains included sexual interest, satisfaction with sexual functioning, vaginal lubrication, vaginal discomfort, and erectile function. Individuals with and without sexual dysfunction were compared on pain-related outcome variables. Results from this study showed a high prevalence of sexual dysfunction in populations with chronic pain and a positive association between sexual problems and pain severity and psychological concerns. Sex differences were noted, with female participants exhibiting significantly lower sexual satisfaction associated with higher levels of pain, pain-related life interference, depression, and anxiety, whereas these relationships were not significant for male participants. Findings demonstrated that patients with chronic pain experience significant sexual dysfunction, including lack of interest in sexual activity and low satisfaction with their sex lives. Compared with patients without sexual dysfunction, patients with sexual dysfunction reported higher average pain levels and higher depressive symptoms, along with greater anxiety in patients with at least one area of sexual dysfunction. Adding to these findings are the pain-relevant correlates of sexual functioning domains and sex differences in these relationships, with women experiencing additional pain-related problems. Limitations and future research directions are discussed.

The Effect of Sleep Disorders on Sexual Function in Bipolar Disorder in the Remission Period

IntroductionBipolar Disorder(BD) is a common,severe and recurrent disease with significant effects on functionality. Residual symptoms such as sleep disturbance and sexual dysfunction are defined as predictors of poor functioning in remission.ObjectivesThe aim of this study was to investigate the correlation between sleep disorder and severity of sexual dysfunction in patients with BD in remission.MethodsThe study was conducted with 100 female and 100 male BD patients in remission. The sociodemographic and clinical characteristics were recorded by interview with the patients and the patients were given the Young Mania Rating Scale(YMRS),Hamilton Depression Rating Scale(HAM-D),Pittsburg Sleep Quality Index(PSQI),Epworth Sleepiness Scale(ESS),Female Sexual Function Scale(FSFI) and International Index of Erectile Function(IIFF-15)for the assesment of symptom severity.ResultsThe frequency of “sleep disorder” was 45.5% and the frequency of ’’daytime sleepiness’’ was 5.5%.In women the mean FSFI score was 26.06±5.14 and sexual dysfunction frequency was 48%.In men,the mean IIEF score was 59.63±8.34 and erectile dysfunction frequency was 56%. There was a statistically significant negative correlation between total FSFI score with HAM-D(r=-0.592, p <0.001),ESS (r=-0.330, p=0.001)and PSQI(r=-0.557, p<0.001)and between total IIEF score with HAM-D(r=-0.509, p<0.001),ESS(r=-0.361, p<0.001)and PSQI(r=-0.511,p<0.001). Sexual function scores in both women and men with sleep problems were significantly lower than those without sleep problems(23.56±4.71vs.28.56±4.31and53.88±7.10vs.63.80±6.56 respectively). Multiple linear regression analysis also showed that total sleep quality scores were an effective factor on sexual function in women(OR:2.74,%95CI[0,799-0,127];p=0,007) and men(OR:2.45, %95CI[1.577-0.164];p=0,016) with BD.ConclusionsThere was an increased incidence of sexual dysfunction in bipolar patients with sleep disorders.Treatment of sleep disorders is important for improving sexual function in bipolar patients for both genders.DisclosureNo significant relationships.

Prevalence of sexual dysfunction in the patients suffering from depression: A cross-sectional study

Background: A significant number of patients suffering from depression experience various sexual dysfunctions like decreased sexual interest, erectile disorders, premature ejaculation and anorgasmia. The evaluation of the prevalence of sexual dysfunction in depression is complicated by the fact that both medications as well as the depressive state itself may affect sexual desire and arousal. This study aimed to assess the prevalence of sexual dysfunction in cases of depression, and to check the correlation of severity of depression with severity of sexual dysfunction. Methods: This study was a cross-sectional non-interventional hospital based study. Diagnosis of depressive disorder was made according to ICD-10. The severity of depression was assessed using Beck Depression Inventory (BDI-II) and the severity of sexual dysfunction was assessed using Arizona Sexual Experience scale (ASEX). The data obtained was analysed using SPSS Version 23. Results: A total of 100 depressed patients diagnosed as per the International Classification of diseases 10 criteria were recruited after their informed consent. Majority of the participants were young lower middle class female; most of the participants were married (50%), homemakers by profession (34%), belonging to a semiurban area (43%). 50% of them (n=50) reported having sexual dysfunction. The mean BDI-II total score was 17.08±4.206. The mean ASEX total score was 28.28±11.312. The BDI-II score was found to be significantly correlated with the ASEX total score (r=0.686, p<0.001). Conclusion: A significant correlation was found between severity of depression and severity of sexual dysfunction.

A Scoping Review of the Prevalence and Correlates of Sexual Dysfunction in Adults With Substance use Disorders

Substance use may affect sexual functioning in both men and women. Comorbid sexual dysfunction adds to the clinical burden of substance use disorders (SUD). The broad aims were to identify research conduct, types of the available evidence, and research gaps in (i) estimating the incidence, prevalence, type, and severity of sexual dysfunction in adults with SUD; (ii) exploring correlates of sexual dysfunction in SUD. We conducted systematic searches on PubMed, Google Scholar, and Embase for studies published in the English language between August 1954 and November 2020. We included prospective and cross-sectional observational studies that had examined the prevalence or incidence of any sexual dysfunction in adults of either gender with substance use disorders. Review articles and those with an exclusive focus on tobacco use disorders were excluded. The review was registered in PROSPERO. Our search identified 65 relevant articles, including five prospective studies. All the prospective studies and most of the cross-sectional studies (n=40) were done among men and subjects with alcohol (n=20) and opioid (n=23) use disorders in clinical populations. Substance use and sexual dysfunction were assessed by a wide range of instruments. Prospective studies reported a prevalence of sexual dysfunction at 75% and 61% for alcohol and opioid use disorders, respectively. The prevalence of any sexual dysfunction in cross-sectional studies ranged between 15 and 100 percent. Erectile dysfunction was the most commonly studied and observed sexual dysfunction. Comorbidity and socioeconomic deprivation were consistently associated with a higher occurrence of sexual dysfunctions. We did not limit our review by the type of substances and year of publication. We adhered to the standards of conducting and reporting scoping reviews; hence, our review results should be replicable, transparent, and reliable. The wide clinical and methodological heterogeneity precluded a systematic review. Research gaps exist in women, non-clinical population, stimulants, and cannabis use disorders, and effect of treatment of SUD in sexual functioning. The quality of evidence is poor. Ghosh A, Kathiravan S, Sharma K, Mattoo SK. A Scoping Review of the Prevalence and Correlates of Sexual Dysfunction in Adults With Substance use Disorders. J Sex Med 2022;19:216-233.

The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): translation, adaptation and validation of the Polish version for patients with multiple sclerosis and spinal cord injury

BackgroundPolish physicians and researchers lack an extensive and precise instrument in their native language for evaluating sexual dysfunction in individuals with neurogenic disorders. The aim of this study was to create a culturally adapted, validated, Polish language version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15) for persons with multiple sclerosis (MS) and spinal cord injury (SCI).MethodsInternational recommendations and standardized methods for instrument validation were followed. Sexually active patients with MS and SCI completed the MSISQ-15, International Index of Erection Function (IIEF-15, men), and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-31, women). IIEF-15 and PISQ-31 were used as reference questionnaires. Responses were collected at baseline (test) and after 2 weeks (re-test).ResultsWe recruited 299 Polish-speaking patients with MS or SCI. Interviews disclosed that the translated questionnaire had optimal content validity/cross-cultural adaptation. MSISQ-15 scores correlated significantly with the severity of sexual dysfunction as evaluated by IIEF-15 (r = − 0.487) and PISQ-31 (r = − 0.709). These correlations substantiated the high quality construct/criterion validity. An analysis of reliability presented good internal consistency (Cronbach’s alpha of 0.93 for the total score of MS patients and 0.86 for the total score of SCI patients) and reproducibility (intraclass correlation coefficients of 0.91 for the total score of MS patients and 0.92 for the total score of SCI patients). There were no ceiling or floor effects.ConclusionsThe Polish version of MSISQ-15 exhibited excellent measurement properties. It is a suitable and reliable instrument to assess sexual dysfunction in MS and SCI individuals. The Polish MSISQ-15 will enhance routine clinical practice and assist research for neurogenic patients in Poland.

Use of the International Index of Erectile Function to assess sexual dysfunction in the male population with prostate cancer treated by radical prostatectomy – a systematic review

Introduction: Prostate carcinoma is the second most commonly diagnosed cancer among men, accounting for 14.1% of diagnoses and with a 6.8% mortality rate. Among current treatment options, radical prostatectomy is strongly indicated for localized prostate cancer. Although surgical techniques for radical prostatectomy are constantly being improved in terms of effectiveness and safety, postoperative disorders such as stress urinary incontinence and sexual dysfunction, including erectile dysfunction, remain quite common. Aim: The aim of our systematic review is to discuss the prevalence and severity of sexual dysfunction in the population of men suffering from prostate cancer who have been treated by means of radical prostatectomy. Material and methods: For the purposes of this systematic review we undertook a search of the literature in five databases using the English and Polish languages. We have focused on studies which assess sexual dysfunction using the International Index of Erectile Function (IIEF) questionnaire. Results and discussion: A total of 145 potentially relevant studies was retrieved. After selection, it was determined that 5 studies fulfilled the eligibility criteria and these were selected for qualitative synthesis. Our systematic review supports the finding that impairment of sexual function continues during the first 12 months after radical prostatectomy. Conclusions: Sexual dysfunction is a common complication after radical prostatectomy, and recovery takes at least 12 months. The male population with prostate cancer is at risk of sexual dysfunction even before radical prostatectomy due to age, comorbidities and mental factors related to the course of the disease.

Pelvic Floor Dysfunction And Its Effect On Quality Of Sexual Life.

Pelvic floor disorders (PFD) are extremely common; 1 in 3 parous women will experience urinary incontinence, 1 in 2 will develop pelvic organ prolapse, whereas 1 in 10 experience fecal incontinence. PFD are often associated with a significant reduction in women's psychological, social, and sexual well-being. To review the current literature on sexual dysfunction related to PFD. A literature search was conducted using PubMed and key words including sexual dysfunction, prolapse, incontinence, pelvic floor dysfunction, and surgical repair. The outcome was to identify the nature and severity of sexual dysfunction in women with PFD. The prevalence of sexual dysfunction is estimated to be around 30-50% in the general population, whereas in women with PFD, the reported incidence rises to 50-83%. The leading factors cited for the reduction in a woman's sexual experience included worries about the image of their vagina for women with pelvic organ prolapse, dyspareunia and coital incontinence in women with urinary incontinence, and fear of soiling when dealing with anal incontinence. Pelvic floor muscle training has been associated with an improvement in sexual function. 11% of parous women will have surgery for pelvic organ prolapse, yet limited data are available on the impact of surgical intervention on sexual function. Native tissue repair of pelvic organ prolapse is associated with an improvement in sexual function, whereas posterior repair with levatorplasty and vaginal mesh repair can increase the risk of postsurgical dyspareunia. Subtotal hysterectomy is not associated with improved sexual function compared with traditional total hysterectomy. It is clear there is an urgent need for further research on the effects of surgery for PFD on sexual function. To date, most studies have focused on anatomic rather than functional outcomes. Verbeek M, Hayward L. Pelvic Floor Dysfunction and Its Effect on Quality of Sexual Life. Sex Med Rev 2019;7:559-564.

Incidence and severity of sexual dysfunction among women with breast cancer: a meta-analysis based on female sexual function index.

Previous meta-analyses have examined the prevalence of sexual dysfunction among women with cancer, but there is no breast cancer (BC)-specific study. We therefore conducted a meta-analysis to examine the prevalence and severity of female sexual dysfunction (FSD) in women with BC. We searched PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and VIP for relevant studies published between April 2000 and January 2017. Data were extracted from studies which assessed FSD prevalence and sexual function in women with BC using the female sexual function index (FSFI). Meta-analyses were performed by pooling the prevalence rates of FSD and total FSFI scores. Meta regression was performed to explore the sources of heterogeneity. We selected 19 published studies involving a total of 2684 women with BC. In this study population, overall FSD prevalence was 73.4% (95% confidence interval (CI) 64.0%, 82.8%), and the total FSFI score was 19.28 (95% CI 17.39, 21.16). Among Asian, American, and European women with BC, there were significant differences in FSD prevalence (P < 0.001), and there was marginally significant difference (P = 0.07) in sexual function between these groups. There was also a marginally significant difference between individuals from mainland China and from other countries in FSD prevalence (P = 0.06) and FSFI score (P = 0.07). Overall, women with BC have high FSD prevalence and low sexual function. American women with BC have a higher average FSD prevalence and lower average sexual function than Asian women with BC. The FSD prevalence in women with BC in mainland China was slightly higher than in other countries.

Causative Relationship Between Drug Abuse And Sexual Dysfunction in Males

Objectives: Most studies investigate sexual dysfunction in drug abusers. However, no data is available about drug abuse in patients with sexual dysfunction especially in Upper Egypt. Therefore, this study aims to assess the pattern of drug abuse in patients with sexual dysfunction, and its potential impact on hormonal profile. Material and Methods: The study included 100 male patients with history of sexual dysfunction for at least 6 months. Initial evaluation with history, general & local examinations were done. Sexual dysfunction was evaluated with the Arabic version of Sexual health inventory for men (SHIM), Erection hardness score (EHS), and the Arabic Index of Premature Ejaculation (AIPE). Morning blood sample was used for assessment of Total Testosterone (TT), Luteinizing Hormone (LH), and Follicle Stimulating Hormone (FSH). Urine sample was screened by (ABON™ Multi-Drug) dipstick kits for the following drug abuse tramadol, opiate, THC (Cannabis), amphetamine, barbiturate, cocaine and benzodiazepines. Positive results were confirmed by the Immunoassay drug analyzer through the use of specific antibodies. Results: Patients' characteristics showed age 39 (31-45) years with 52% were smoker. Sexual dysfunction complaints included PE (76%), ED (57%), and combined (43%), with average duration of 11 (8-18) months. Patients' hormonal profile showed TT 6.3 (2.67-7.55) ng/ml, FSH 3.5(1.86-5.01) mIU/ml, and LH 3.1(2.1-5) mIU/ml. SHIM, EHS, and AIPE were 15 (12-19), 3 (2-3), and 19(16-24) respectively. Urine screening was positive in 39 % (39/100). Confirmation by drug analyzer revealed 4 patients were false positive. Therefore, the final result for drug abuse was 35% (35/100); with the most common drug was tramadol 19% (19/100) followed by THC (Cannabis) 12% (12/100). Patients with positive drug abuse had significantly higher smoking percent (p=<0.0001), higher driver occupation (p=0.018), and higher positive drug abuse history (p=<0.0001). There were no significant changes in both the sexual dysfunction severity and hormonal profile between positive and negative drug abuse groups. Through binary logistic regression, both smoking (OR=22.39, 95% CI: 4.20- 119.19, p=<0.0001), and history of drug abuse (OR=20.26, 95% CI: 5.21- 78.76, p=<0.0001) are significantly independent predictors for positive drug abuse test. Conclusions: Drug abuse is prevalent among Egyptian male patients with sexual dysfunction, especially tramadol. The drug abuse is common among smoker, and driver occupation. However, no hormonal disturbance could be shown in drug abuse patients. More patient awareness and legal regulations should be considered to reduce drug abuse in Egypt.

Sexual dysfunction in women with Parkinson's disease.

Sexual dysfunction in women with Parkinson's disease is poorly understood and research in this area is scarce. The objectives of this study were sexual function characterization in female Parkinson's disease patients, description of sexual dysfunctions, correlation with disease characteristics, and comparison with matched healthy controls. Social and demographic data from consecutive female patients with Parkinson's disease and matched healthy controls were collected. The following instruments were used: UPDRS, the Hoehn and Yahr scale, the Beck Depression Inventory-II, the Female Sexual Function Index, and the Sexual Dysfunction Inventory. The only exclusion criterion was cognitive deterioration precluding comprehension of the study scope and its instruments. Of the 95 patients identified, 61 were included. Mean age was 66 years (range 40-89 years), and mean disease duration was seven years (range 1-18 years). Twenty-nine presented an akinetic-rigid syndrome, 25 tremoric disease, and, the remaining, a mixed type of disease. Mean "on" total/part III UPDRS scores were 46 ± 15.0 and 31 ± 8.9. Sexual dysfunction was present in 86.9% of patients and 79.0% of controls, according to the Female Sexual Function Index (p < .01), and in 57.4% of patients and 22.6% of controls, according to the Sexual Dysfunction Inventory (p < .001). Multivariate binary logistic regression identified age and depressive symptoms as positive predictors in the severity of sexual dysfunction. Disease duration, UPDRS part III score, Hoehn and Yahr stage, and antiparkinsonian medication did not show significant predictive value. Sexual dysfunction is more prevalent in women with Parkinson's disease than in controls and is predicted by older age and severity of depressive symptoms. © 2016 International Parkinson and Movement Disorder Society.

Co-relationship between sexual dysfunction and high-risk sexual behavior in patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence.

Introduction:People suffering from substance dependence suffer from various sexual dysfunctions and are at risk for indulging in various high-risk sexual behaviors and thus are vulnerable to acquire various infections such as HIV/AIDS and other sexually transmitted infections.AIM:The aim of the study was to evaluate the correlation between sexual dysfunction and high-risk sexual behavior in opioid-dependent men receiving buprenorphine and naltrexone maintenance therapy.Materials and Methods:Semi-structured questionnaire, brief male sexual functioning inventory and HIV-risk taking behavior scale was administered to a sample of 60 sexually active men, receiving buprenorphine (n = 30) and naltrexone (n = 30) maintenance therapy for opioid dependence.Results:The main outcomes are correlation between severity of sexual dysfunction and HIV-risk taking behavior. The study results showed 83% of the men on buprenorphine and 90% on naltrexone reported at least one of the sexual dysfunction symptoms. There was a negative correlation between sexual dysfunction and HIV-risk taking behavior that suggest severe the dysfunction, higher the risk taking behavior. Significant correlation was present with overall sexual dysfunction and HIV-risk taking behavior (P = 0.028 and in naltrexone receiving group premature ejaculation versus HIV-risk taking behavior however, (P = 0.022, P < 0.05) there were no significant differences among both the groups except above findings.Conclusion:Conclusion was treatment is associated with sexual dysfunctions and HIV-risk taking behavior, which has clinical implication. Future research should explore this further using biochemical analyses.

Sexual dysfunction in outpatients with schizophrenia in Turkey: a cross-sectional study.

BackgroundSexual dysfunction is one of several factors related to medication compliance in patients taking antipsychotic medication but the magnitude of this problem is unknown.AimCompare the self-reported sexual functioning of clinically stable patients with schizophrenia taking antipsychotic medication to that of healthy controls using the Turkish version of the 5-item Arizona Sexual Experience Scale (ASEX). This scale, which has previously been validated in Turkey, assesses 5 components of sexual function: sex drive, sexual arousal, vaginal lubrication/penile erection, ability to achieve orgasm, and satisfaction with orgasm.MethodsThe Scale for the Assessment of Positive Symptoms, the Scale for Assessment of Negative Symptoms, and ASEX were administered to 101 clinically stable outpatients with schizophrenia (38 females and 63 males). The ASEX was also administered to 89 control subjects (41 females and 48 males) without a history of mental illness. Respondents were classified as having sexual dysfunction if ASEX total score (range 5-30) >18, if any ASEX item score (range 1-6) ≥ 5, or if 3 or more ASEX items ≥4.ResultsMale patients with schizophrenia have significantly more self-reported sexual dysfunction than healthy controls (46% vs. 8%). The prevalence of sexual dysfunction is higher in female patients than in male patients (68% vs. 46%), but it was also very high in healthy female controls (68%), so the sexual dysfunction of female patients cannot be attributed to their illness or to the medications they are taking. Within the patient group, there was no significant relationship between the severity of positive or negative symptoms and the severity of sexual dysfunction, and the severity of sexual function was not different between patients taking first-generation or second-generation antipsychotic medications.ConclusionsThe very different findings by gender in Turkey highlights the importance of assessing location-specific and gender-specific sexual norms when trying to assess the role of mental illness and medications on sexual functioning. Prospective studies are needed to distinguish the relative importance of cultural norms, the schizophrenic illness, and the use of antipsychotic medication in the etiology and course of sexual dysfunction among individuals with schizophrenia.

Sexual dysfunction in women with lymphoma: Prevalence and etiologies.

e20594 Background: Sexual dysfunction is reported during and after treatment for lymphoma and causes a substantial burden on women. However, the prevalence and severity of sexual dysfunction in thi...